CN107789484B - 一种治疗***的中药组合物及其制备方法 - Google Patents
一种治疗***的中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN107789484B CN107789484B CN201711340659.1A CN201711340659A CN107789484B CN 107789484 B CN107789484 B CN 107789484B CN 201711340659 A CN201711340659 A CN 201711340659A CN 107789484 B CN107789484 B CN 107789484B
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- traditional chinese
- concentrated solution
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 79
- 239000003814 drug Substances 0.000 title claims abstract description 68
- 208000037093 Menstruation Disturbances Diseases 0.000 title claims abstract description 41
- 206010027339 Menstruation irregular Diseases 0.000 title claims abstract description 40
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 244000197580 Poria cocos Species 0.000 claims abstract description 31
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 31
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims abstract description 21
- 235000017803 cinnamon Nutrition 0.000 claims abstract description 21
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 19
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 19
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 19
- 235000011477 liquorice Nutrition 0.000 claims abstract description 19
- 235000017784 Mespilus germanica Nutrition 0.000 claims abstract description 18
- 244000182216 Mimusops elengi Species 0.000 claims abstract description 18
- 235000000560 Mimusops elengi Nutrition 0.000 claims abstract description 18
- 235000007837 Vangueria infausta Nutrition 0.000 claims abstract description 18
- 108010010803 Gelatin Proteins 0.000 claims abstract description 14
- 229920000159 gelatin Polymers 0.000 claims abstract description 14
- 239000008273 gelatin Substances 0.000 claims abstract description 14
- 235000019322 gelatine Nutrition 0.000 claims abstract description 14
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 14
- 239000000243 solution Substances 0.000 claims description 64
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 53
- 239000000463 material Substances 0.000 claims description 45
- 238000001914 filtration Methods 0.000 claims description 25
- 239000000706 filtrate Substances 0.000 claims description 24
- 238000010992 reflux Methods 0.000 claims description 24
- 238000007873 sieving Methods 0.000 claims description 24
- 108010052008 colla corii asini Proteins 0.000 claims description 23
- 238000000605 extraction Methods 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 238000010438 heat treatment Methods 0.000 claims description 16
- 239000008187 granular material Substances 0.000 claims description 15
- 238000010298 pulverizing process Methods 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 10
- 239000006187 pill Substances 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 8
- 238000002791 soaking Methods 0.000 claims description 8
- 239000002994 raw material Substances 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 6
- 239000011259 mixed solution Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 abstract description 32
- 239000008280 blood Substances 0.000 abstract description 32
- 210000004185 liver Anatomy 0.000 abstract description 32
- 230000000694 effects Effects 0.000 abstract description 31
- 230000001105 regulatory effect Effects 0.000 abstract description 14
- 210000003734 kidney Anatomy 0.000 abstract description 11
- 230000005906 menstruation Effects 0.000 abstract description 11
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract description 8
- 206010022437 insomnia Diseases 0.000 abstract description 8
- 208000024891 symptom Diseases 0.000 abstract description 6
- 210000004291 uterus Anatomy 0.000 abstract description 5
- 238000010792 warming Methods 0.000 abstract description 4
- 230000000052 comparative effect Effects 0.000 description 29
- 241000699670 Mus sp. Species 0.000 description 17
- 208000019255 Menstrual disease Diseases 0.000 description 12
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 12
- 210000003743 erythrocyte Anatomy 0.000 description 9
- 230000007812 deficiency Effects 0.000 description 8
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 7
- 235000009508 confectionery Nutrition 0.000 description 7
- 238000009499 grossing Methods 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 241000287828 Gallus gallus Species 0.000 description 6
- 238000010172 mouse model Methods 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 235000019640 taste Nutrition 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241000233805 Phoenix Species 0.000 description 5
- 206010047700 Vomiting Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000002175 menstrual effect Effects 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- 206010033557 Palpitations Diseases 0.000 description 4
- 210000001015 abdomen Anatomy 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 238000007908 dry granulation Methods 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 208000007106 menorrhagia Diseases 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- 201000000736 Amenorrhea Diseases 0.000 description 3
- 206010001928 Amenorrhoea Diseases 0.000 description 3
- 238000012449 Kunming mouse Methods 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 208000001431 Psychomotor Agitation Diseases 0.000 description 3
- 206010038743 Restlessness Diseases 0.000 description 3
- 231100000540 amenorrhea Toxicity 0.000 description 3
- 208000022531 anorexia Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000001914 calming effect Effects 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000027758 ovulation cycle Effects 0.000 description 3
- 230000003860 sleep quality Effects 0.000 description 3
- 230000002936 tranquilizing effect Effects 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 208000036581 Haemorrhagic anaemia Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 235000001188 Peltandra virginica Nutrition 0.000 description 2
- 208000012886 Vertigo Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 231100000889 vertigo Toxicity 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010021033 Hypomenorrhoea Diseases 0.000 description 1
- 241000218195 Lauraceae Species 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 244000241872 Lycium chinense Species 0.000 description 1
- 235000015468 Lycium chinense Nutrition 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241001468611 Polygonatum cyrtonema Species 0.000 description 1
- 241000037826 Polygonatum kingianum Species 0.000 description 1
- 241000222341 Polyporaceae Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000219100 Rhamnaceae Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 1
- 241000767840 Semiaquilegia Species 0.000 description 1
- 241000208292 Solanaceae Species 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 241001247821 Ziziphus Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000002445 liver protective agent Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种治疗***的中药组合物及其制备方法,该中药组合物包括阿胶8~12份、黄精18~22份、红枣18~22份、枸杞8~12份、茯苓10~14份、肉桂8~12份、橘皮10~14份和甘草8~12份。本发明中药组合物具有养血调经、补益肝肾、暖宫的功效,能有效治疗和调理***,同时改善失眠症状,提高患者生活质量。
Description
技术领域
本发明属于中药技术领域,具体涉及一种治疗***的中药组合物及其制备方法。
背景技术
***是妇科常见疾病,主要表现为***或经期、经量、经色、经质的异常,包括月经先期、月经后期、经期延长、闭经等,或是在月经前后出现腰腹痛及全身症状。***是妇科临床常见病、多发病,严重者可能影响日常工作及生活,应该引起高度关注。
在中医看来月经的产生是肾气、天葵、冲任、气血作用于胞宫,并在其他脏腑、经络的协同作用下使胞宫定期藏泻而产生的生理现象。引起***的原因是多方面的,但主要与肾、肝、脾等脏腑功能失常、气血阴阳失调有关,另外与女性“血少气多”的生理特点也有密切的联系。其中,***与肝密切相关。叶天士认为“女子以肝为先天”,肝主疏泄,肝脏具有疏通气机,畅达的功效,主要表现为促进血液运行和津液的代谢,调畅一切情志活动,通调一切***和***。肝主藏血,具有贮藏血液,调节血量和防止出血的生理功能。月经的常与变和“肝主疏泄”功能密切相关。《内经》曰:“肝为将军之官,谋虑出焉。”及“故人卧血归于肝”。张锡纯曰:“月事不行,由于血室,而血室为肾之副脏,实借肝主疏泄以为流通,方书所谓肝行肾之气也。”冲任之流通。亦取决于肝之疏泄,因足厥阴肝经络阴器,循少腹,与冲任二脉互为沟通。同时肝的藏血功能和疏泄作用须相互协调,冲任二脉得其所助,则二脉通畅,血脉流畅,经候如常。许多研究表明,现今许多年轻女性素多抑郁,精神学习工作压力过大,肝的疏泄功能失常,以致肝郁气滞,肝气郁结,肝失疏泄,冲任气血失于畅达而瘀滞于内,瘀血内阻,血脉失畅,***。
现有公开了多种治疗***的中药组方,但是大多偏重于益气养血,忽视了对肝肾的补益。如中国专利申请CN 107007749A公开了一种补益气血、调经养巢的组合物,包括黄精、甘草、茯苓、肉桂、益母草、当归、红糖、阿胶、五味子、龟甲、枸杞子、熟地和巴戟天。其具有益气补血、滋阴补肾、养血通络的作用,能够调节内分泌,改善***、痛经闭经、宫寒***等症,还能改善失眠多梦、烦躁易怒等症。但是该组方药味众多,对肝肾的补益作用欠缺,且调理效果还有待提高。
发明内容
为了解决现有技术中存在的问题(如配方复杂、疗效欠佳等),本发明提供了一种治疗***的中药组合物,本发明中药组合物易吸收,生物利用度好,具有养血调经、补益肝肾、暖宫的功效,能治疗和调理***,同时改善失眠症状。
为了实现上述目的,本发明的技术方案如下:
一种治疗***的中药组合物,包括以下重量份计的制备原料:阿胶8~12份、黄精18~22份、红枣18~22份、枸杞8~12份、茯苓10~14份、肉桂8~12份、橘皮10~14份和甘草8~12份。
作为本发明优选的实施方式,所述治疗***的中药组合物包括以下重量份计的制备原料:阿胶10份、黄精20份、红枣20份、枸杞10份、茯苓12份、肉桂10份、橘皮12份和甘草10份。
优选的,所述中药组合物为口服制剂。
更优选的,所述中药组合物为颗粒剂、胶囊剂、口服液和丸剂。
相应地,本发明还提供了上述治疗***的中药组合物的制备方法,具体包括以下步骤:
S1、取配方量的黄精、肉桂和甘草,粉碎,过10目筛,加入4~6倍药材量的水,浸泡1~2h后,加热,回流提取2~3h,过滤,滤液真空减压浓缩至原体积的1/4~1/3,制得浓缩液A;
S2、取配方量的红枣、枸杞和橘皮,粉碎,过10目筛,加入5~7倍药材量的乙醇,回流提取2~3h,过滤,滤液真空减压浓缩至原体积的1/4~1/3,制得浓缩液B;
S3、取配方量的茯苓,粉碎,过10目筛,加入4~6倍药材量的乙醇,回流提取2~3h,过滤,滤液真空减压浓缩至原体积的1/4~1/3,制得茯苓浓缩液;
S4、取配方量的阿胶,粉碎成小块,加入3~5倍药材量的水,小火加热熬煮至完全融化,制得阿胶液;
S5、将所述浓缩液A、浓缩液B、茯苓浓缩液和阿胶液混合,混合液在真空减压浓缩至60℃下相对密度为1.10~1.20的浸膏,减压干燥,粉碎,制得治疗***的中药组合物。
进一步的,所述步骤S2中乙醇的体积百分比浓度为30~50%。
进一步的,所述步骤S3中乙醇的体积百分比浓度为80~90%。
本发明中药组合物中各原料的来源、性味及功效如下:
阿胶为马科动物驴的干皮或鲜皮经煎煮、浓缩而制成的固体胶。性平、味甘。补血滋阴、润肺、止血。主治血虚萎黄、眩晕心悸、肌萎无力、心烦不眠、肺燥咳嗽等。先打碎再加水烊化
黄精为百合科植物黄精、多花黄精和滇黄精的根茎。性平,味甘。补中益气,润心肺,强筋骨。主治虚损寒热,肺痨咳血,病后体虚食少,筋骨软弱,风湿疼痛,风癞癣疾。
红枣为鼠李科枣属植物枣的干燥成熟果实。性温,味甘。补脾和胃,益气生津,调营卫,解药毒。主治胃虚食少,脾弱便溏,气血津液不足,营卫不和,心悸怔忡,妇人赃躁。
枸杞为茄科植物宁夏枸杞的干燥成熟果实。性平,味甘。滋补肝肾,益精明目。主治虚劳精亏,腰膝酸痛,眩晕耳鸣,内热消渴,血虚萎黄,目昏不明。
茯苓为多孔菌科真菌茯苓的干燥菌核。性平,味甘、淡。利水渗湿,益脾宁心。主治气虚劳伤,水肿,痰饮,呕吐,腹泻,遗精,热淋,惊悸,健忘等症。
肉桂为樟科植物肉桂的干燥树皮。性大热,味辛、甘。补火助阳,引火归源,散寒止痛,活血通经。主治阳痿、宫冷、心腹冷痛、虚寒吐泻、经闭、痛经、温经通脉。
橘皮为芸香科植物橘及其栽培变种的干燥成熟果皮。味辛苦,性温。理气健脾,燥湿化痰。主治胸脘胀满,食少吐泻,咳嗽痰多。治胸腹胀满,不思饮食,呕吐哕逆,咳嗽痰多。亦解鱼、蟹毒。
甘草为豆科植物甘草、胀果甘草或光果甘草的干燥根及根茎。味甘,性平。补脾益气、止咳祛痰、缓急定痛、调和药性。
方中阿胶、黄精补血养肝、活血调经,红枣、枸杞疏肝解肝理气,茯苓、肉桂活血通经以通肝经之滞,兼行少腹之瘀,橘皮、甘草健脾燥湿、和胃理气,且调和诸药,诸药合用,共奏疏肝、调肝、养肝,活血通经之效,对***,特别是肝郁型***有很好的治疗效果。并且,本发明中药组合物还具有清心除烦、安心宁神的功效,能改善患者失眠症状,改善睡眠质量。
因此,与现有技术相比,本发明的优势在于:
(1)本发明治疗***的中药组合物易吸收,生物利用度高,安全可靠,具有养血调经、补益肝肾、暖宫,清心除烦、安心宁神的功效,对妇女***有很好的治疗效果,同时能够改善失眠症状,改善睡眠质量,提高患者生活质量。
(2)本发明治疗***的中药组合物可被制成颗粒剂、口服液和丸剂等各种口服剂型,且制备方法简单,条件可控,工艺稳定,可工业化生产,有利于推广应用。
具体实施方式
以下通过具体实施例进一步描述本发明,本发明不仅仅限于以下实施例。在本发明的范围内或者在不脱离本发明的内容、精神和范围内,对本发明进行的变更、组合或替换,对于本领域的技术人员来说是显而易见的,且包含在本发明的范围之内。
实施例1、本发明治疗***的中药组合物及其制备
配方:阿胶8kg、黄精18kg、红枣18kg、枸杞8kg、茯苓10kg、肉桂8kg、橘皮10kg和甘草8kg。
制备方法:S1、取配方量的黄精、肉桂和甘草,粉碎,过10目筛,加入136kg水,浸泡1h后,加热,回流提取2h,过滤,滤液真空减压浓缩至原体积的1/4,制得浓缩液A;
S2、取配方量的红枣、枸杞和橘皮,粉碎,过10目筛,加入180kg体积百分比浓度为30%的乙醇,回流提取2h,过滤,滤液真空减压浓缩至原体积的1/4,制得浓缩液B;
S3、取配方量的茯苓,粉碎,过10目筛,加入40kg体积百分比浓度为80%的乙醇,回流提取2h,过滤,滤液真空减压浓缩至原体积的1/4,制得茯苓浓缩液;
S4、取配方量的阿胶,粉碎成小块,加入24kg水,小火加热熬煮至完全融化,制得阿胶液;
S5、将所述浓缩液A、浓缩液B、茯苓浓缩液和阿胶液混合,混合液在真空减压浓缩至60℃下相对密度为1.10的浸膏,减压干燥,粉碎,制得治疗***的中药组合物。
按照常规工艺,将上述中药组合物药粉与葡萄糖等辅料混均,干法制粒,整粒,即制得本发明治疗***的中药组合物的颗粒剂。
实施例2、本发明治疗***的中药组合物及其制备
配方:阿胶12kg、黄精22kg、红枣22kg、枸杞12kg、茯苓14kg、肉桂12kg、橘皮14kg和甘草12kg。
制备方法:S1、取配方量的黄精、肉桂和甘草,粉碎,过10目筛,加入276kg水,浸泡2h后,加热,回流提取3h,过滤,滤液真空减压浓缩至原体积的1/3,制得浓缩液A;
S2、取配方量的红枣、枸杞和橘皮,粉碎,过10目筛,加入336kg体积百分比浓度为50%的乙醇,回流提取3h,过滤,滤液真空减压浓缩至原体积的1/3,制得浓缩液B;
S3、取配方量的茯苓,粉碎,过10目筛,加入84kg体积百分比浓度为90%的乙醇,回流提取3h,过滤,滤液真空减压浓缩至原体积的1/3,制得茯苓浓缩液;
S4、取配方量的阿胶,粉碎成小块,加入60kg水,小火加热熬煮至完全融化,制得阿胶液;
S5、将所述浓缩液A、浓缩液B、茯苓浓缩液和阿胶液混合,混合液在真空减压浓缩至60℃下相对密度为1.20的浸膏,减压干燥,粉碎,制得治疗***的中药组合物。
按照常规工艺,将上述中药组合物药粉与葡萄糖等辅料混均,干法制粒,整粒,即制得本发明治疗***的中药组合物的颗粒剂。
实施例3、本发明治疗***的中药组合物及其制备
配方:阿胶10kg、黄精20kg、红枣20kg、枸杞10kg、茯苓12kg、肉桂10kg、橘皮12kg和甘草10kg。
制备方法:S1、取配方量的黄精、肉桂和甘草,粉碎,过10目筛,加入200kg水,浸泡2h后,加热,回流提取2h,过滤,滤液真空减压浓缩至原体积的1/4,制得浓缩液A;
S2、取配方量的红枣、枸杞和橘皮,粉碎,过10目筛,加入252kg体积百分比浓度为40%的乙醇,回流提取3h,过滤,滤液真空减压浓缩至原体积的1/4,制得浓缩液B;
S3、取配方量的茯苓,粉碎,过10目筛,加入60kg体积百分比浓度为85%的乙醇,回流提取3h,过滤,滤液真空减压浓缩至原体积的1/4,制得茯苓浓缩液;
S4、取配方量的阿胶,粉碎成小块,加入40kg水,小火加热熬煮至完全融化,制得阿胶液;
S5、将所述浓缩液A、浓缩液B、茯苓浓缩液和阿胶液混合,混合液在真空减压浓缩至60℃下相对密度为1.10的浸膏,减压干燥,粉碎,制得治疗***的中药组合物。
按照常规工艺,将上述中药组合物药粉与葡萄糖等辅料混均,干法制粒,整粒,即制得本发明治疗***的中药组合物的颗粒剂。
实施例4、本发明治疗***的中药组合物及其制备
配方:阿胶12kg、黄精18kg、红枣18kg、枸杞12kg、茯苓12kg、肉桂10kg、橘皮10kg和甘草8kg。
制备方法:S1、取配方量的黄精、肉桂和甘草,粉碎,过10目筛,加入216kg水,浸泡1h后,加热,回流提取3h,过滤,滤液真空减压浓缩至原体积的1/3,制得浓缩液A;
S2、取配方量的红枣、枸杞和橘皮,粉碎,过10目筛,加入200kg体积百分比浓度为50%的乙醇,回流提取2h,过滤,滤液真空减压浓缩至原体积的1/3,制得浓缩液B;
S3、取配方量的茯苓,粉碎,过10目筛,加入60kg体积百分比浓度为80%的乙醇,回流提取2h,过滤,滤液真空减压浓缩至原体积的1/4,制得茯苓浓缩液;
S4、取配方量的阿胶,粉碎成小块,加入36kg水,小火加热熬煮至完全融化,制得阿胶液;
S5、将所述浓缩液A、浓缩液B、茯苓浓缩液和阿胶液混合,混合液在真空减压浓缩至60℃下相对密度为1.20的浸膏,减压干燥,粉碎,制得治疗***的中药组合物。
按照常规工艺,将上述中药组合物药粉与葡萄糖等辅料混均,干法制粒,整粒,即制得本发明治疗***的中药组合物的颗粒剂。
实施例5、本发明治疗***的中药组合物及其制备
配方:阿胶8kg、黄精20kg、红枣22kg、枸杞10kg、茯苓10kg、肉桂12kg、橘皮12kg和甘草10kg。
制备方法:S1、取配方量的黄精、肉桂和甘草,粉碎,过10目筛,加入210kg水,浸泡2h后,加热,回流提取2h,过滤,滤液真空减压浓缩至原体积的1/4,制得浓缩液A;
S2、取配方量的红枣、枸杞和橘皮,粉碎,过10目筛,加入308kg体积百分比浓度为30%的乙醇,回流提取3h,过滤,滤液真空减压浓缩至原体积的1/4,制得浓缩液B;
S3、取配方量的茯苓,粉碎,过10目筛,加入40kg体积百分比浓度为90%的乙醇,回流提取2h,过滤,滤液真空减压浓缩至原体积的1/3,制得茯苓浓缩液;
S4、取配方量的阿胶,粉碎成小块,加入40kg水,小火加热熬煮至完全融化,制得阿胶液;
S5、将所述浓缩液A、浓缩液B、茯苓浓缩液和阿胶液混合,混合液在真空减压浓缩至60℃下相对密度为1.10的浸膏,减压干燥,粉碎,制得治疗***的中药组合物。
按照常规工艺,取上述中药组合物药粉,加入3倍药粉重的体积分数为65%乙醇,充分搅拌,室温下静置24h,取上清液,减压回收乙醇直至上清液无醇味,得到药液;往所述药液中加入6倍药液重的水进行稀释,静置后过滤即得本发明治疗***的中药组合物的口服液。
对比例1~5中药组合物的配方如下:
对比例1~5中药组合物的制备方法参考实施例3,制得相应的中药组合物。
对比例6
本对比例的配方同实施例3。
制备方法:与实施例3相比,区别仅在于:步骤S2中采用体积百分比浓度为60%的乙醇作为提取溶剂;步骤S3中体积百分比浓度为70%的乙醇作为提取溶剂。
对比例7
本对比例的配方同实施例3。
制备方法:与实施例3相比,区别仅在于:步骤S2中采用水作为提取溶剂。
对比例8
本对比例的配方同实施例3。
制备方法:与实施例3相比,区别仅在于:步骤S2和步骤S3中均采用水作为提取溶剂。
试验例一、本发明治疗***的中药组合物对四氯化碳致肝损伤小鼠模型的影响
1.材料:
昆明种小鼠150只,体重26~30g,雌雄各半,由中科院上海研究所提供;四氯化碳(CCl4)(郑州化学试剂二厂生产),本发明实施例1~5中药组合物,对比例1~8中药组合物。
2.方法:
昆明种小鼠150只,雌雄各半,实验条件下预养2d,将小鼠随机分为正常对照组、CCl4对照组和实施例1~5、对比例1~8共15组,每组10只。正常对照组和CCl4对照组每天均灌胃给等容量的蒸馏水。实施例1~5、对比例1~8组分别给予本发明实施例1~5、对比例1~8制得的中药组合物1.0g/kg灌胃给药。一次1d,连续给药7d。末次给药2h后除正常对照组外,各组均按10ml/kg的剂量腹腔注射0.1%的CCl4,禁食16h后进行全采血测AST及ALT,结果见表1。
3.结果:
表1各中药组对四氯化碳致肝损伤小鼠模型血清AST、ALT的影响
组别 | n | AST(U/dl) | ALT(U/dl) |
正常对照组 | 10 | 108.26±12.47 | 83.12±10.39 |
CCl<sub>4</sub>对照组 | 10 | 1301.20±89.12 | 2210.41±142.30 |
实施例1组 | 10 | 757.57±63.15** | 1263.63±77.49** |
实施例2组 | 10 | 792.32±64.60** | 1381.03±79.20** |
实施例3组 | 10 | 663.91±60.14** | 1084.12±71.70** |
实施例4组 | 10 | 723.84±62.10** | 1194.86±70.38** |
实施例5组 | 10 | 750.32±69.08** | 1207.50±75.26** |
对比例1组 | 10 | 1200.36±93.82 | 2027.19±150.09 |
对比例2组 | 10 | 1170.25±95.40 | 2109.30±147.25 |
对比例3组 | 10 | 972.02±80.98* | 1772.10±101.60* |
对比例4组 | 10 | 990.68±79.05* | 1809.44±103.27* |
对比例5组 | 10 | 950.70±77.63* | 1700.57±97.73* |
对比例6组 | 10 | 964.06±79.01* | 1750.41±95.08* |
对比例7组 | 10 | 1080.93±93.40 | 2009.27±130.29 |
对比例8组 | 10 | 1217.80±90.07 | 2108.19±145.06 |
注:与CCl4对照组比较,*p<0.05,**p<0.01。
由上表1可见:
(1)与CCl4对照组相比,本发明实施例1~5组小鼠血清AST、ALT含量降低,具有极显著差异(p<0.01),提示本发明中药组合物能显著抑制CCl4所致的小鼠血清ALT和AST的升高,具有显著的保肝作用。
(2)与本发明实施例3相比,对比例1和对比例2缺少某些原料,结果其小鼠血清中ALT、AST含量与CCl4对照组相比,没有显著差异,基本不具有保肝作用。
(3)对比例3、对比例4和对比例5的原料配比均不在本发明的范围内,结果其小鼠血清中ALT、AST含量与本发明实施例组相比有所升高,护肝作用下降。
(3)与本发明实施例3相比,对比例6、对比例7和对比例8改变了提取溶剂,结果其小鼠血清中ALT、AST含量与CCl4对照组相比,仅有对比例6具有显著差异(p<0.05),对比例7和8没有显著差异,护肝作用明显下降,提示各药材不同极性部位的结合会影响其药效。
(4)试验期间,各组均无小鼠死亡,其中本发明实施例1~5组均未发现有小鼠出现体形消瘦、脱毛、活动量减少、呕吐等不良状况。
另外,给正常小鼠灌服本发明实施例1~5的中药组合物1.0g/kg,一次1d,连续给药7d,末次给药后禁食16h,采全血测ALT及AST。结果显示,给药组小鼠血中的ALT和AST含量与正常组相比无明显差异,提示本发明中药组合物对正常小鼠的肝功能指标无明显影响。
试验例二、本发明治疗***的对失血性贫血小鼠模型的影响
1.材料:
昆明种小鼠90只,体重26~30g,雌雄各半,由中科院上海研究所提供;乌鸡白凤丸(药都制药集团股份有限公司国药准字Z13021070),本发明实施例3~5中药组合物,对比例3~6中药组合物。
2.方法:将90只小鼠,测Hb(血红蛋白)及RBC(红细胞)后眶后静脉丛放血0.5ml/只,24h后尾静脉取血测Hb及RBC,根据测定结果分为9组,每组10只。正常对照组每天均灌胃给等容量的蒸馏水,乌鸡白凤丸组给予乌鸡白凤丸1.0g/kg灌胃给药。实施例3~5、对比例3~6组分别给予本发明实施例3~5、对比例3~6制得的中药组合物1.0g/kg灌胃给药。一次1d,连续给药10天。分别于给药后第3天、6天、10天尾静脉取血测定各组的Hb、RBC值。结果见表2和表3。
3.结果:
表2各中药组对失血性贫血小鼠模型Hb、RBC的影响—造型前后
注:与造型前比较,*p<0.05,**p<0.01。
表3各中药组对失血性贫血小鼠模型Hb、RBC的影响—测试天数
由上表2和表3可见:
(1)各试验组小鼠造型前后Hb、RBC含量明显降低,具有极显著差异,提示造模成功。
(2)灌胃给药后,实施例3~5组小鼠Hb、RBC明显升高,其效果与现有乌鸡白凤丸相当,且实施例3组略优于乌鸡白凤丸组,提示本发明中药组合物能使失血性贫血小鼠模型的Hb和RBC明显升高,具有显著的补血作用。
(3)灌胃给药后,对比例3~6组小鼠Hb、RBC有所升高,但其提升幅度不及实施例3~5组。
试验例三、本发明治疗***的中药组合物的临床治疗效果研究
邀请300名患有***的志愿者,随机分组,治疗组240例,对照组60例。治疗组服用本发明实施例3中药颗粒剂,每次10g,每日2次,1个月为1个疗程。对照组服用乌鸡白凤丸(药都制药集团股份有限公司国药准字Z13021070)一次9克,一日1次,1个月为1个疗程。治疗1个疗程后,研究结果表明治疗组总有效率为95.3%,未发生不良反应,现将临床研究结果总结如下:
(1)临床观察结果表明:采用本发明实施例3中药颗粒剂治疗妇女***的总有效率为95.0%,而对照组采用乌鸡白凤丸治疗妇女***的总有效率为91.7%。从显效和有效率上看,治疗组为65.8%,对照组为63.3%,表明本发明中药组合物在治疗***上优于现有的乌鸡白凤丸,是一较好的治疗***的新药。
(2)从中医辩证分型角度看:本发明中药组合物对肝郁型***具有很好的疗效,总有效率达97.8%。
(3)从西医所分各症状的疗效看:本发明中药组合物对月经过多、月经过少、经期延长和痛经的总有效率分别为97.0%、95.6%、96.7%和96.4%,表明本发明中药组合物对月经过多、月经过少、经期延长和痛经的疗效确切。
(4)本发明在治疗组240例观察中,除发现2例自感口干外,未发现有其他不良反应和毒副作用,表明本发明中药组合物是安全可靠的。
(5)本发明在治疗组240例观察中,有50例伴有失眠症状(病程最短1个月,最长2年),经1疗程治疗后,总有效率为90.0%,表明本发明实施例3中药颗粒剂还能改善失眠,延长睡眠时间,增加睡眠深度,提高睡眠质量,提示本发明中药组合物具有一定的清心除烦、安心宁神的功效。
以上仅是本发明的优选实施方式,应当指出的是,上述优选实施方式不应视为对本发明的限制,本发明的保护范围应当以权利要求所限定的范围为准。对于本技术领域的普通技术人员来说,在不脱离本发明的精神和范围内,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (5)
1.一种治疗***的中药组合物,其特征在于,由以下重量份计的原料制备而成:阿胶8~12份、黄精18~22份、红枣18~22份、枸杞8~12份、茯苓10~14份、肉桂8~12份、橘皮10~14份和甘草8~12份;
所述治疗***的中药组合物由以下方法制备而成:
S1、取配方量的黄精、肉桂和甘草,粉碎,过10目筛,加入4~6倍药材量的水,浸泡1~2h后,加热,回流提取2~3h,过滤,滤液真空减压浓缩至原体积的1/4~1/3,制得浓缩液A;
S2、取配方量的红枣、枸杞和橘皮,粉碎,过10目筛,加入5~7倍药材量的乙醇,回流提取2~3h,过滤,滤液真空减压浓缩至原体积的1/4~1/3,制得浓缩液B;
S3、取配方量的茯苓,粉碎,过10目筛,加入4~6倍药材量的乙醇,回流提取2~3h,过滤,滤液真空减压浓缩至原体积的1/4~1/3,制得茯苓浓缩液;
S4、取配方量的阿胶,粉碎成小块,加入3~5倍药材量的水,小火加热熬煮至完全融化,制得阿胶液;
S5、将所述浓缩液A、浓缩液B、茯苓浓缩液和阿胶液混合,混合液在真空减压浓缩至60℃下相对密度为1.10~1.20的浸膏,减压干燥,粉碎,制得治疗***的中药组合物;
所述步骤S2中乙醇的体积百分比浓度为30~50%;
所述步骤S3中乙醇的体积百分比浓度为80~90%。
2.根据权利要求1所述治疗***的中药组合物,其特征在于,由以下重量份计的原料制备而成:阿胶10份、黄精20份、红枣20份、枸杞10份、茯苓12份、肉桂10份、橘皮12份和甘草10份。
3.根据权利要求1或2所述治疗***的中药组合物,其特征在于,所述中药组合物为口服制剂。
4.根据权利要求3所述治疗***的中药组合物,其特征在于,所述中药组合物为颗粒剂、胶囊剂、口服液或丸剂。
5.根据权利要求1或2所述治疗***的中药组合物的制备方法,其特征在于,包括以下步骤:
S1、取配方量的黄精、肉桂和甘草,粉碎,过10目筛,加入4~6倍药材量的水,浸泡1~2h后,加热,回流提取2~3h,过滤,滤液真空减压浓缩至原体积的1/4~1/3,制得浓缩液A;
S2、取配方量的红枣、枸杞和橘皮,粉碎,过10目筛,加入5~7倍药材量的乙醇,回流提取2~3h,过滤,滤液真空减压浓缩至原体积的1/4~1/3,制得浓缩液B;
S3、取配方量的茯苓,粉碎,过10目筛,加入4~6倍药材量的乙醇,回流提取2~3h,过滤,滤液真空减压浓缩至原体积的1/4~1/3,制得茯苓浓缩液;
S4、取配方量的阿胶,粉碎成小块,加入3~5倍药材量的水,小火加热熬煮至完全融化,制得阿胶液;
S5、将所述浓缩液A、浓缩液B、茯苓浓缩液和阿胶液混合,混合液在真空减压浓缩至60℃下相对密度为1.10~1.20的浸膏,减压干燥,粉碎,制得治疗***的中药组合物;
所述步骤S2中乙醇的体积百分比浓度为30~50%;
所述步骤S3中乙醇的体积百分比浓度为80~90%。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711340659.1A CN107789484B (zh) | 2017-12-14 | 2017-12-14 | 一种治疗***的中药组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711340659.1A CN107789484B (zh) | 2017-12-14 | 2017-12-14 | 一种治疗***的中药组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107789484A CN107789484A (zh) | 2018-03-13 |
CN107789484B true CN107789484B (zh) | 2020-11-10 |
Family
ID=61537594
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711340659.1A Expired - Fee Related CN107789484B (zh) | 2017-12-14 | 2017-12-14 | 一种治疗***的中药组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107789484B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109820199A (zh) * | 2019-04-03 | 2019-05-31 | 江西安顺堂生物科技有限公司 | 一种补气血、调节内分泌的保健品 |
CN110447868A (zh) * | 2019-08-20 | 2019-11-15 | 广东伊家汤药品有限公司 | 一种调理月经的汤品及其制备方法 |
CN114081935A (zh) * | 2021-09-24 | 2022-02-25 | 江西御辕堂电子商务有限公司 | 一种滋阴补血膏植物饮品 |
CN113940973A (zh) * | 2021-12-07 | 2022-01-18 | 喜园(广东)生物科技有限公司 | 一种补血调经的中药组合物及其制备方法和应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102283935A (zh) * | 2011-09-08 | 2011-12-21 | 厦门鹰君药业有限公司 | 益母桂圆膏的制备方法 |
CN107007749A (zh) * | 2017-06-12 | 2017-08-04 | 董斌 | 一种补益气血、调经养巢的膏滋及其制备方法 |
CN107184730A (zh) * | 2017-05-26 | 2017-09-22 | 四川品物生农业科技有限公司 | 经期调理中药配方及袋泡茶 |
CN107412513A (zh) * | 2017-07-21 | 2017-12-01 | 刘道鹏 | 一种***茶及其制备方法 |
-
2017
- 2017-12-14 CN CN201711340659.1A patent/CN107789484B/zh not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102283935A (zh) * | 2011-09-08 | 2011-12-21 | 厦门鹰君药业有限公司 | 益母桂圆膏的制备方法 |
CN107184730A (zh) * | 2017-05-26 | 2017-09-22 | 四川品物生农业科技有限公司 | 经期调理中药配方及袋泡茶 |
CN107007749A (zh) * | 2017-06-12 | 2017-08-04 | 董斌 | 一种补益气血、调经养巢的膏滋及其制备方法 |
CN107412513A (zh) * | 2017-07-21 | 2017-12-01 | 刘道鹏 | 一种***茶及其制备方法 |
Non-Patent Citations (1)
Title |
---|
补中益气汤加味妇科临证三则;石新勇;《实用中医内科杂志》;20081231;第22卷(第11期);63 * |
Also Published As
Publication number | Publication date |
---|---|
CN107789484A (zh) | 2018-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102078520B (zh) | 一种治疗神经性头痛的中药制剂及其制备方法 | |
CN107789484B (zh) | 一种治疗***的中药组合物及其制备方法 | |
CN104436018A (zh) | ***的药物及其制备方法 | |
CN115252740A (zh) | 一种用于调理***的中药组合物及其制备方法 | |
CN104491236A (zh) | 一种治疗原发性高血压的中药制剂及其制备方法 | |
CN104383515A (zh) | 一种治疗气血亏虚型产后风湿的中药组合物 | |
CN104225166A (zh) | 一种治疗闭经的中药组合物及其制备方法 | |
CN103736017A (zh) | 一种治疗肋间神经痛的中药组合物及其制备方法 | |
CN105497811A (zh) | 一种治疗肝硬化的中药组合物及其制备工艺 | |
CN104547598A (zh) | 一种治疗神经衰弱的中药制剂及制备方法 | |
CN104435567A (zh) | 一种含绞股蓝的治疗痛风的中药组合物 | |
CN109876127B (zh) | 一种养血当归胶囊及其制备方法 | |
CN103860773A (zh) | 用于治疗心肌缺血的中药组合物及其制备方法 | |
CN112587645A (zh) | 治疗***症的中药组合物、中药制剂和中药制品 | |
CN104857370A (zh) | 一种治疗乳腺癌症的中药组合物 | |
CN105362630A (zh) | 一种治疗更年期综合症的药物组合物及其制备方法 | |
CN104888098A (zh) | 一种用于关节置换后静脉血栓的中药制剂及制备方法 | |
CN111870650A (zh) | 一种侗族药酒及其制备方法 | |
CN104840902A (zh) | 一种治疗卵巢肿瘤的中药制剂 | |
CN108567926B (zh) | 一种治疗瘀血阻络型自身免疫性肝炎的中药组合物及其制备方法 | |
CN101757265B (zh) | 一种治疗迁延性肝炎的中药组合物及其制备方法 | |
CN105381414A (zh) | 一种治疗***肿块及囊性增生的中药制剂及其制备方法 | |
CN104524149A (zh) | 一种防治急性肾炎的药物组合物及其应用 | |
CN105311527A (zh) | 一种用于治疗子宫内膜移位症的中药制剂及其制备方法 | |
CN104491237A (zh) | 一种中药制剂在制备治疗原发性高血压药物中的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20201110 |
|
CF01 | Termination of patent right due to non-payment of annual fee |